Compare XBIT & TLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | TLS |
|---|---|---|
| Founded | 2005 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.4M | 358.4M |
| IPO Year | 2015 | 2020 |
| Metric | XBIT | TLS |
|---|---|---|
| Price | $2.37 | $4.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.90 |
| AVG Volume (30 Days) | 27.1K | ★ 858.1K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.51 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $164,805,000.00 |
| Revenue This Year | N/A | $18.72 |
| Revenue Next Year | N/A | $14.62 |
| P/E Ratio | ★ N/A | $148.67 |
| Revenue Growth | N/A | ★ 52.21 |
| 52 Week Low | $2.09 | $2.37 |
| 52 Week High | $3.61 | $8.36 |
| Indicator | XBIT | TLS |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 40.34 |
| Support Level | $2.26 | $3.88 |
| Resistance Level | $2.69 | $4.65 |
| Average True Range (ATR) | 0.07 | 0.34 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 10.34 | 0.00 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Telos Corp offers technology solutions and services that empower and protect the world's security-conscious organizations. The company delivers efficient, adaptable, and secure solutions that protect people, organizations, and information across government and industry. The company conducts its business through two reportable and operating segments: Security Solutions and Secure Networks. The Security Solutions segment is focused on cybersecurity, cloud, and identity solutions, and secure messaging through Xacta, Telos AMHS, and Telos ID offerings. The Secure Networks segment provides secure networking architectures and solutions to customers through secure mobility solutions, network management, and defense services. The majority of revenue is from Secure Networks.